Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.

Addiction science & clinical practice - 13 Sept 2014

Hendershot Christian S

Abstract excerpt

Despite advances in characterizing genetic influences on addiction liability and treatment response, clinical applications of these efforts have been slow to evolve. Although challenges to clinical translation remain, stakeholders already face decisions about evidentiary thresholds for the uptake of pharmacogenetic tests in practice. There is optimism about potential pharmacogenetic applications for the treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol-Related Disorders
Share to Evidence-Based Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Naltrexone

Share to Narcotic Antagonists

Share to Pharmacogenetics

Share to Precision Medicine

Share to Randomized Controlled Trials as Topic

Share to Receptors, Opioid, mu

Source

Open in PubMed Open full text

Identifiers

PMID: 25217046
DOI: 10.1186/1940-0640-9-20
PMCID: PMC4165632

Genes

OPRM1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds.PMID 25217046Read ↗

Pharmacogenetics of alcohol, nicotine and drug addiction treatments.Semantic proximity Read ↗

Pharmacogenetically driven treatments for alcoholism: are we there yet?Semantic proximity Read ↗

A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder.Semantic proximity Read ↗

The μ-opioid receptor and treatment response to naltrexone.Semantic proximity Read ↗

The pharmacogenetics of alcohol use disorder.Semantic proximity Read ↗

Advances in Medications and Tailoring Treatment for Alcohol Use DisorderSemantic proximity Read ↗

Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.Semantic proximity Read ↗

Pharmacogenetics of alcohol and alcohol dependence treatment.Semantic proximity Read ↗

Pharmacogenetic approaches to the treatment of alcohol addiction.Semantic proximity Read ↗

Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis.Semantic proximity Read ↗

COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.Semantic proximity Read ↗

[Pharmacogenetics and the treatment of addiction].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.